(Bloomberg) -- Just when it looked like the worst was over for the Spanish family behind one of the world’s biggest medical fortunes, its financial woes plumbed to a new low. The Grifols family ...

However, Grifols, a global healthcare company and ... BARDA’s mission is to develop ‘medical countermeasures’ to address the public health and medical consequences of chemical, biological ...

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and checkpoint-resistant cancers, and a subsidiary of Grifols, announced today ...

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almost $6 ...

The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 23,000 ...

Shares in Grifols jumped in early trading Friday after the company reported better-than-expected third-quarter sales driven by a strong performance of its biopharma division. Shares traded 4.7% ...

A successful preclinical study of this potentially innovative therapeutic could lead to an FDA license for one of the first medical treatments for sulfur mustard ocular injury Grifols also plans ...

GRIFOLS transfer bags are used for sterile preservation and administration of blood components. Blood components can be obtained, stored and preserved without contact with the environment ensuring ...

BARCELONA, Spain, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF ... could eventually license what would be one of the first medical treatments to counteract the long-term effects of sulfur ...